The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
The dawn of a new era of targeted lipid-lowering therapies
Open accessAbstract
Lipid risk factors for cardiovascular disease depend in part on lifestyle, but optimum control of lipids often demands additional measures. Low-density lipoprotein (LDL) doubtless contributes causally to atherosclerosis. Recent human genetic findings have substantiated a number of novel targets for lipid-lowering therapy including apolipoprotein C-III, angiopoietin-like protein 3 and 4, apolipoprotein V, and ATP citrate lyase. These discoveries coupled with advances in biotechnology development afford new avenues for management of LDL and other aspects of lipid risk. Beyond LDL, new treatments targeting triglyceride-rich lipoproteins and lipoprotein(a) have become available and have entered clinical development. Biological and RNA-directed agents have joined traditional small-molecule approaches, which themselves have undergone considerable refinement. Innovative targeting strategies have increased efficacy of some of these novel interventions and markedly improved their tolerability. Gene-editing approaches have appeared on the horizon of lipid management. This article reviews this progress offering insight into novel biological and therapeutic discoveries, and places them into a practical patient care perspective.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“experts in both regulatory agencies in the USA and the European Union (EU)—from the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA)—approved highly purified EPA, icosapent ethyl, for cardiovascular prevention in patients with dyslipidaemia.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [113]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
Self-citationAlirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317
Libby, P., Buring, J. E., Badimon, L., Hansson, G. K., Deanfield, J., Bittencourt, M. S., Tokgözoğlu, L., & Lewis, E. F. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0106-z · Cited by 3,211
Self-citationSequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Cited by
Sorted by citations
2024 ESC Guidelines for the management of chronic coronary syndromes
Vrints, C. J., Andreotti, F., Koskinas, K. C., Rosselló, X., Adamo, M., Ainslie, J., BANNING, A. P., Budaj, A., Buechel, R. R., Chiariello, G. A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae177 · Cited by 3,521
Ridker, P. M., Bhatt, D. L., Pradhan, A. D., Glynn, R. J., MacFadyen, J. G., & Nissen, S. E. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00215-5 · Cited by 724
Inflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women
Ridker, P. M., Moorthy, M. V., Cook, N. R., Rifai, N., Lee, I.-M. M., & Buring, J. E. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2405182 · Cited by 317
Low-Dose Colchicine for Secondary Prevention of Coronary Artery Disease
Nelson, K. A., Fuster, V., & Ridker, P. M. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.05.055 · Cited by 211
Du, Z., & Qin, Y. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12010363 · Cited by 140
Yu, M., Yang, Y., Dong, S., Zhao, C., Yang, F., Yuan, Y.-F., Liao, Y.-H., He, S.-L., Liu, K., Wei, F., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.069808 · Cited by 126
Hayden, M. R. (2023) · Medicina · doi:10.3390/medicina59030561 · Cited by 131
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Michaeli, D. T., Michaeli, J. C., Albers, S., Boch, T., & Michaeli, T. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00594-5 · Cited by 109
Rouland, A., Masson, D., Lagrost, L., Vergès, B. L., Gautier, T., & Bouillet, B. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01703-5 · Cited by 106
High lipoprotein(a): Actionable strategies for risk assessment and mitigation
Reyes‐Soffer, G., Yeang, C., Michos, E. D., Boatwright, W., & Ballantyne, C. M. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100651 · Cited by 84
Triglyceride and Triglyceride-Rich Lipoproteins in Atherosclerosis
Zhang, B., Yin, F., Qiao, Y.-N., & Guo, S. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.909151 · Cited by 83
Structural Elucidation and Activities of Cordyceps militaris-Derived Polysaccharides: A Review
Miao, M., Yu, W., Li, Y., Sun, Y., & Guo, S. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.898674 · Cited by 73
Markus, M. R. P., Ittermann, T., Mariño, J., Schipf, S., Bahls, M., Könemann, S., Chamling, B., Völzke, H., Damasceno, N. R. T., Santos, R. D., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf281 · Cited by 58
Mach, F., Visseren, F. L. J., Cater, N. B., Salhi, N., Soronen, J., Ray, K. K., Delgado, V., Jukema, J. W., Laufs, U., Zamorano, J.-L., et al. (2024) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2024.07.001 · Cited by 57
Self-citationProhaska, T. A., Alexander, V. J., Karwatowska‐Prokopczuk, E., Tami, J. A., Xia, S., Witztum, J. L., & Tsimikas, S. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.04.007 · Cited by 48
Nanomaterials Responsive to Endogenous Biomarkers for Cardiovascular Disease Theranostics
Wei, C., Jiang, Z., Li, C., Li, P., & Fu, Q. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202214655 · Cited by 43
Chasing LDL cholesterol to the bottom — PCSK9 in perspective
Libby, P., & Tokgözoğlu, L. S. (2022) · Nature Cardiovascular Research · doi:10.1038/s44161-022-00085-x · Cited by 41
Self-citationKim, K. A., Kim, N. J., & Choo, E. H. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad331 · Cited by 36
Celastrol functions as an emerging manager of lipid metabolism: Mechanism and therapeutic potential
Gu, J., Shi, Y., Zhu, N., Li, H., Zhang, C., & Li, Q. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114981 · Cited by 36
Advances in Dyslipidaemia Treatments: Focusing on ApoC3 and ANGPTL3 Inhibitors
Tomlinson, B., Wu, Q., Zhong, Y.-M., & Li, Y. (2024) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2024.13.1.2 · Cited by 39
Engineered exosomes as a prospective therapy for diabetic foot ulcers
Guo, L., Xiao, D., Xing, H., Yang, G., & Yang, X. (2024) · Burns & Trauma · doi:10.1093/burnst/tkae023 · Cited by 40
Han, M., Huang, K., Shen, C., Hu, H., Liu, F., Li, J., Yang, X., Chen, J.-C., Liu, X., Cao, J., et al. (2024) · Stroke · doi:10.1161/strokeaha.124.046811 · Cited by 37
Zeng, G., Zhang, C., Song, Y., Zhang, Z., Xu, J., Liu, Z., Tang, X., Wang, X., Chen, Y., Zhang, Y., et al. (2024) · BMC Medicine · doi:10.1186/s12916-024-03823-z · Cited by 38
Lipoproteins, Cholesterol, and Atherosclerotic Cardiovascular Disease in East Asians and Europeans
Doi, T., Langsted, A., & Nordestgaard, B. G. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22013 · Cited by 37
Diagnostic and Therapeutic Aptamers
Mauro, V. D., Lauta, F. C., Modica, J., Appleton, S. L., de Franciscis, V., & Catalucci, D. (2023) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2023.06.013 · Cited by 32
Zhang, L. N., Wang, C., Hu, W., Bu, T., Sun, W., Zhou, T., Qiu, S., Wei, M., Xing, H., Li, Z., et al. (2023) · Theranostics · doi:10.7150/thno.87484 · Cited by 32
Elías-López, D., Doi, T., Nordestgaard, B. G., & Kobylecki, C. J. (2023) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000999 · Cited by 30
Shi, J., Yang, M. M., Yang, S., Fan, F., Zhang, J., Miao, Y., Hua, Y., Zhang, J., Cheng, Y., Liu, S., et al. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155489 · Cited by 30
New approaches to triglyceride reduction: is there any hope left?
Filtz, A., Parihar, S., Greenberg, G. S., Park, C. M., Scotti, A., Lorenzatti, D., Badimon, J. J., Soffer, D. E., Toth, P. P., Lavie, C. J., et al. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100648 · Cited by 26
Hypertriglyceridemia Therapy: Past, Present and Future Perspectives
Canfora, I., & Pierno, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179727 · Cited by 27
Liu, Y., Lu, K., Zhang, R., Hu, D., Yang, Z., Zeng, J., & Cai, W. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00574 · Cited by 25
May, L. T., Bartolo, B. A. D., Harrison, D. G., Guzik, T. J., Drummond, G. R., Figtree, G. A., Ritchie, R. H., Rye, K., & de Haan, J. B. (2022) · Clinical Science · doi:10.1042/cs20210862 · Cited by 23
Taskinen, M., Matikainen, N., Björnson, E., Söderlund, S., Inkeri, J., Hakkarainen, A., Parviainen, H., Sihlbom, C., Thorsell, A., Andersson, L. K., et al. (2023) · Diabetologia · doi:10.1007/s00125-023-06008-0 · Cited by 23
Ballantyne, C. M., & Norata, G. D. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf606 · Cited by 23
Silbernagel, G., Chen, Y., Rief, M., Kleber, M. E., Hoffmann, M. M., Stojaković, T., Stang, A., Sarzynski, M. A., Bouchard, C., März, W., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad261 · Cited by 21
Klingenberg, R., Leiherer, A., Dobrev, D., Kaski, J. C., Levkau, B., März, W., Sossalla, S. T., von Eckardstein, A., & Drexel, H. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf093 · Cited by 21
Updates in Small Interfering RNA for the Treatment of Dyslipidemias
Carugo, S., Sirtori, C. R., Gelpi, G., Corsini, A., Tokgözoğlu, L. S., & Ruscica, M. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01156-5 · Cited by 22
Self-citationPrecision cardiovascular medicine: shifting the innovation paradigm
Aikawa, M., Sonawane, A. R., Chelvanambi, S., Asano, T., Halu, A., Matamalas, J. T., Singh, S. A., Uchida, S., Aïkawa, E., Arenas, À., et al. (2025) · Frontiers in Science · doi:10.3389/fsci.2025.1474469 · Cited by 24
Tang, C., Wang, H., Guo, L., Zou, C., Hu, J., Zhang, H., Zhou, W., & Yang, G. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c11227 · Cited by 21
Gene therapy for polygenic or complex diseases
Wu, T., Hu, Y., & Tang, L. V. (2024) · Biomarker Research · doi:10.1186/s40364-024-00618-5 · Cited by 24
Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol
Mohamed, F., Mansfield, B. S., & Raal, F. J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12155082 · Cited by 20
Luo, F., Cao, J., Chen, Q., Liu, L., Yang, T., Bai, X., Ma, W., Lin, C., Zhou, T., Zhan, J., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008146 · Cited by 18
Duan, H. Q., Li, H., Liu, T., Chen, Y., Luo, M., Shi, Y., Zhou, J., Rashed, M. M. A., Zhai, K., Li, L., et al. (2024) · ACS Omega · doi:10.1021/acsomega.4c03738 · Cited by 18
Modder, M., Panhuis, W. I. H., Li, M., Afkir, S., Dorn, A. L., Pronk, A. C. M., Streefland, T. C. M., Lalai, R. A., Pierrou, S. E., Nilsson, S. K., et al. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae195 · Cited by 17
Farnier, M., Santos, R. D., Cosı́n-Sales, J., Владиславович, Е. М., Liu, J., Granados, D., Santoni, S., Khan, I., & Catapano, A. L. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac214 · Cited by 17
Zhang, L., Hu, W., Qiu, Z., Li, Z., & Bian, J. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00179 · Cited by 17
Lipid Disorders Management Strategies (2024) in Prediabetic and Diabetic Patients
Gaiţă, L., Timar, B., Timar, R. Z., Fras, Z., Gaiță, D. I., & Banach, M. (2024) · Pharmaceuticals · doi:10.3390/ph17020219 · Cited by 29
Adamidis, P. S., Pantazi, D., Moschonas, I. C., Liberopoulos, E. N., & Tselepis, A. D. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11030072 · Cited by 19
Wang, L., Huang, S., Liang, X., Zhou, J.-L., Han, Y., He, J., & Xu, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1377470 · Cited by 17
Adam, S., Maas, S. L., Huchzermeier, R., Rakateli, L., Abschlag, K., Hohl, M., Liao, L., Bartneck, M., Teunissen, M., Wouters, K., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105293 · Cited by 17
Lee‐Rueckert, M., Jauhiainen, M., Kovanen, P. T., & Escolá‐Gil, J. C. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.06.008 · Cited by 16
Doi, T., Nordestgaard, B. G., & Langsted, A. (2023) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000799 · Cited by 17
Dai, Y., Chen, Q., Zhang, D., Li, M., & Liu, W. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02014-2 · Cited by 18
Arriola, E., de Castro, J., García-Campelo, R., Bernárdez, B., Bernabé, R., Bruna, J., Dómine, M., Isla, D., Juan, Ó., López‐Fernández, T., et al. (2024) · Clinical Drug Investigation · doi:10.1007/s40261-024-01379-7 · Cited by 17
Inflammasomes as the molecular hub of cardiovascular-metabolic-immune comorbidity networks
Qian, X., Sun, J. M., Li, F., Li, X., Hu, X., Dong, N., & Li, G. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1690443 · Cited by 18
Wen, Y., Chen, Y., & Konrad, R. J. (2023) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000910 · Cited by 15
Lee, H., Crawford, E. B., Cho, S. M. J., Krawisz, A. K., Juraschek, S. P., Cluett, J., Lee, H., Kim, H. C., Natarajan, P., Wadhera, R. K., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.09.1607 · Cited by 14
Jiang, Y., Dang, Y., Wu, Q. Y., Yuan, B., Gao, L., & You, C. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1366307 · Cited by 16
Nanomedicine-based drug delivery strategies for the treatment of atherosclerosis
Lin, Y., Lin, R., Lin, H.-B., & Shen, S. (2024) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2024.100189 · Cited by 14
Polymeric Nanomaterials for Atherosclerosis Diagnosis and Treatment
Liu, X., Zhang, K., Yin, M., Bai, Y., Hu, C., Lei, Z., Meng, F., & Luo, L. (2025) · Polymer science & technology. · doi:10.1021/polymscitech.4c00055 · Cited by 14
Liu, Y., Guo, F.-M., Qiu, W.-J., Gao, Y.-P., Han, X., & Shen, B. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd12100384 · Cited by 14
Xue, J., Liu, Y., Liu, B., Jia, X., Fang, X., Qin, S., & Zhang, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1444117 · Cited by 12
Liu, H., Hastings, M. H., Kitchen, R. R., Xiao, C., Guerra, J. R. B., Kuznetsov, A., & Rosenzweig, A. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.318138 · Cited by 12
Liñares, A., Dopico, J., Blanco, C., Pico, A., Sobrino, T., Blanco, J., & Leira, Y. (2024) · Clinical Oral Implants Research · doi:10.1111/clr.14339 · Cited by 11
Lipid-Lowering Medications for Managing Dyslipidemia: A Narrative Review
Alqahtani, M. S., Alzibali, K. F., Mahdi, A. M. M., Alharbi, O. M. A., Harbi, R. H. A., Alkhaldi, H. S. M., Alsayafi, Z. A. A., Bisher, F. H. A., Buqurayn, M. H., & Alharbi, M. M. (2024) · Cureus · doi:10.7759/cureus.65202 · Cited by 11
Stilbene glycosides alleviate atherosclerosis partly by promoting lipophagy of dendritic cells
Yang, Y., Bai, D., Jiang, L., Chen, Y., Wang, M., Wang, W., Wang, H., He, Q., Bu, G., Long, J., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113223 · Cited by 12
Macrophage-endothelial cell crosstalk drives atherosclerotic plaque formation and progression
Zhang, C., Zhang, Y., Yu, Y., Zhou, M., Zhang, J., Fu, K., & Li, Y. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177879 · Cited by 10
Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?
Surma, S., Sahebkar, A., & Banach, M. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01186-z · Cited by 10
Zan, C., An, J., Wu, Z., & Li, S. (2023) · Nanotheranostics · doi:10.7150/ntno.82654 · Cited by 10
An update on inclisiran for the treatment of elevated LDL cholesterol
Barkas, F., & Ray, K. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2337253 · Cited by 9
Targeting residual cardiovascular risk in the statin era: cholesterol or inflammation?
Liuzzo, G., & Patrono, C. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad241 · Cited by 9
Luo, X., He, C., Yang, B., Yin, S., & Li, L. (2025) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-024-05106-y · Cited by 8
Li, X., Huang, X., Song, K., Liu, J., Jin, Y., Li, T., Zhang, L., & Zhang, H. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156691 · Cited by 9
Gao, S., Huang, S., Liu, X., Yu, M., & Li, W. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s547594 · Cited by 9
Screening, diagnosis, and treatment of familial hypercholesterolaemia: a call to action
Crea, F. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac479 · Cited by 9
Xiao, Q., Wang, L., Wang, J., Wang, M., Wang, D. W., & Ding, H. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102011 · Cited by 8
Reprogramming and targeting of cholesterol metabolism in tumor-associated macrophages
Ma, Q., Zhu, Y., Zhang, D., Su, X., Jiang, C., Zhang, Y., Zhang, X., Han, N., Shu, G., Yin, G., et al. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb00236b · Cited by 7
Microenvironments‐Targeted Nanomaterials for Atherosclerosis Therapy
Song, C., Ling, H., Yang, G., & Ding, J. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202421512 · Cited by 7
Han, M., Zhou, J., Wan, Z., Chen, M., Yan, M., Feng, W. S., Wang, G., Zhang, J., Zhang, L., Yan, L., et al. (2025) · Nutrition & Metabolism · doi:10.1186/s12986-025-00982-5 · Cited by 8
Lp(a) Levels in Relatives of Patients with Acute Coronary Syndrome and Elevated Lp(a): HER(a) Study
Fernández-Olmo, M. R., Bailén, M. C., Quesada, M. M., Mansilla, C. R., Toro, M. M., Suárez, A. L., García, M. L., Quiroga, G. A. C., Bernal, B. C., Cruces, S. O., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13082256 · Cited by 7
Conte, E., Perone, F., Cosyns, B., Dweck, M. R., Donal, E., Gonçalves, I., Ibáñez, B., Kaski, J. C., Maurovich‐Horvat, P., Onuma, Y., et al. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf594 · Cited by 6
Zhu, X., Chen, Y., Xu, B., Mou, J., Wang, M., Gu, Q., Sun, Q., Li, M., Zhao, C., Zeng, M. Y., et al. (2025) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.08.036 · Cited by 7
P2Y6 receptor: A promising therapeutic target for atherosclerosis
Li, L., Lai, L., Qiu, D., Ding, Y., Yu, M., Zhang, T., Wang, Z., & Wang, S. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177513 · Cited by 5
Chen, Y., Wang, G., Jiang, Y., Qian, K., Liu, Y., Qiu, C., & Huang, P. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157120 · Cited by 5
Shishkova, D. K., Kanonykina, A., Андреевич, К. Е., Евгеньевна, Т. А., Morozova, A., Poddubnyak, A., Sinitskaya, А. V., Sinitsky, M. Y., Markova, V. E., Lazebnaya, A. A., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311259 · Cited by 5
Schmidt, L. E., Speidl, W. S., Tsimikas, S., & Mayr, M. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad294 · Cited by 5
Tan, M., Wang, J., Chen, Z., & Xie, X. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1400130 · Cited by 5
Yang, Z., Li, Y.-J., Yang, M., Xu, Y. X. Z., Yao, J., Wang, K., & Gao, Y. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-05066-z · Cited by 5
Heterozygosity for ADP-ribosylation factor 6 suppresses the burden and severity of atherosclerosis
Gogulamudi, V., Islam, M. T., Durrant, J., Adeyemo, A. O., Trott, D. W., Hyuhn, M. H., Zhu, W.-Q., Donato, A. J., Walker, A. E., & Lesniewski, L. (2023) · PLoS ONE · doi:10.1371/journal.pone.0285253 · Cited by 8
Andersson, D. P., Littmann, K., Kindborg, G., Eklund, D., Sejersen, K., Yan, J., Hogling, D. E., Parini, P., & Brinck, J. W. (2024) · European Heart Journal Open · doi:10.1093/ehjopen/oeae010 · Cited by 4
Atherosclerosis prediction: three pathways, stronger insights
Rocha, V. Z. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf396 · Cited by 4
Orally deliverable biomimetic nucleic acid therapies for targeted treatment of atherosclerosis
Li, C., Chen, Y., Li, Y., Liu, H., Yang, S., Lin, Y., Qi, Y., Han, S., Dou, Y., Luo, G., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.07.039 · Cited by 5
Targeting hypercholesterolaemia: challenges and opportunities
Crea, F. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad415 · Cited by 4
Zhu, L., Li, N., Shi, H., Shao, G., & Sun, L. (2024) · European journal of medical research · doi:10.1186/s40001-024-02014-z · Cited by 4
Liu, D., Zhang, J., Zhang, X., Jiang, F., Wu, Y., Yang, B., Li, X., Fan, X., Han, L., Sun, Y., et al. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1454918 · Cited by 4
Fu, L., Liu, Q., Cheng, H., Zhao, X., Xiong, J., & Mi, J. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.038857 · Cited by 4
Small interfering RNA (siRNA) in dyslipidemia: a systematic review on safety and efficacy of siRNA
Alla, S. S. M., Shah, D. J., Meyur, S., Agarwal, P., Alla, D., Moraboina, S. L., Ghadvaje, G. V., Bayeh, R. G., Malireddi, A., Shajan, T., et al. (2025) · Journal of Experimental Pharmacology · doi:10.2147/jep.s521579 · Cited by 4
The LEPIS-HuR-TMOD4 axis regulates hepatic cholesterol homeostasis and accelerates atherosclerosis
LYu, P., Pan, H., Hu, K., Xue, Y., Li, Q., Lin, R., Zheng, S., Guo, Z., & Guo, K. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117554 · Cited by 4
Factors associated with lipid lowering therapy in the multi-ethnic study of atherosclerosis
Cao, J., Guan, W., Nomura, S. J. O., Bhatia, H. S., Garg, P. K., & Tsai, M. Y. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02363-y · Cited by 3
Adjunctive pharmacological strategies for residual risk reduction after myocardial revascularisation
Oshima, A., Serruys, P. W. J. C., Garg, S., McEvoy, J. W., Wood, D. A., Doenst, T., Taggart, D. P., Puskas, J. D., Shajahan, A., Sharif, F., et al. (2026) · EuroIntervention · doi:10.4244/eij-d-25-00598 · Cited by 4
Metadata
- Authors
- Tokgözoğlu, L., & Libby, P.
- Affiliations
- Hacettepe University (TR)
- Brigham and Women's Hospital (US)
- Corresponding author
- Libby, Peter
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-01-20
- Volume
- 43
- Issue
- 34
- Pages
- 3198-3208
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- PMC
- PMC9448630
- OpenAlex
- W4205823791
- Cited by
- 171
- References
- 116
- Citations by year
- 2026: 20 · 2025: 49 · 2024: 59 · 2023: 31 · 2022: 12
- FWCI
- 6.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- European Heart Journal (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (1R01HL134892)
- American Heart Association
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- lipid-lowering therapy, LDL cholesterol, cardiovascular risk, apolipoprotein C-III, ANGPTL3, ANGPTL4, ATP citrate lyase, triglyceride-rich lipoproteins, lipoprotein(a), PCSK9 inhibitors, genome editing, genetic risk factors, atherosclerosis
- MeSH terms
- Hypolipidemic Agents, Cardiovascular Diseases, Humans, Triglycerides, Lipoprotein(a), Dyslipidemias, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
